{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:10:25Z","timestamp":1791090625805,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,5,11]],"date-time":"2014-05-11T00:00:00Z","timestamp":1399766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s00432-014-1683-6","type":"journal-article","created":{"date-parts":[[2014,5,10]],"date-time":"2014-05-10T15:23:25Z","timestamp":1399735405000},"page":"1343-1352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Re-evaluation of cytostatic therapies for meningiomas in vitro"],"prefix":"10.1007","volume":"140","author":[{"given":"Annette","family":"Wilisch-Neumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Pachow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Wallesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Petermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank D.","family":"B\u00f6hmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar","family":"Kirches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mawrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,11]]},"reference":[{"key":"1683_CR1","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/bjophthalmol-2012-302429","volume":"97","author":"GG Adams","year":"2013","unstructured":"Adams GG, Agrawal S, Sekhri R, Peters MJ, Pierce CM (2013) Appearance and location of retinal haemorrhages in critically ill children. Br J Ophthalmol 97:1138\u20131142","journal-title":"Br J Ophthalmol"},{"key":"1683_CR2","first-page":"21","volume":"23","author":"U Andersson","year":"2004","unstructured":"Andersson U, Malmer B, Bergenheim AT, Brannstrom T, Henriksson R (2004) Heterogeneity in the expression of markers for drug resistance in brain tumors. Clin Neuropathol 23:21\u201327","journal-title":"Clin Neuropathol"},{"key":"1683_CR3","doi-asserted-by":"crossref","unstructured":"Andrae N, Kirches E, Hartig R, Haase D, Keilhoff G, Kalinski T, Mawrin C (2012) Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells. Eur J Cancer 48:1831\u20131841","DOI":"10.1016\/j.ejca.2012.01.032"},{"key":"1683_CR4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/03630260701587745","volume":"31","author":"D Bachir","year":"2007","unstructured":"Bachir D, Hulin A, Huet E, Habibi A, Nzouakou R, El Mahrab M, Astier A, Galacteros F (2007) Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease. Hemoglobin 31:417\u2013425","journal-title":"Hemoglobin"},{"key":"1683_CR5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-011-0741-z","volume":"107","author":"MC Chamberlain","year":"2012","unstructured":"Chamberlain MC (2012) Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol 107:315\u2013321","journal-title":"J Neurooncol"},{"key":"1683_CR6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1586\/14737175.4.4.641","volume":"4","author":"MC Chamberlain","year":"2004","unstructured":"Chamberlain MC, Blumenthal DT (2004) Intracranial meningiomas: diagnosis and treatment. Expert Rev Neurother 4:641\u2013648","journal-title":"Expert Rev Neurother"},{"key":"1683_CR7","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.canlet.2012.10.006","volume":"328","author":"X Chen","year":"2013","unstructured":"Chen X, Meng Q, Zhao Y, Liu M, Li D, Yang Y, Sun L, Sui G, Cai L, Dong X (2013) Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer. Cancer Lett 328:318\u2013324","journal-title":"Cancer Lett"},{"key":"1683_CR8","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1158\/0008-5472.CAN-05-0240","volume":"65","author":"I Cuevas","year":"2005","unstructured":"Cuevas I, Slocum A, Jun P, Costello J, Bollen A, Riggins G, McDermott M, Lal A (2005) Meningioma transcript profiles reveal deregulated Notch signaling pathway. Cancer Res 65:5070\u20135075","journal-title":"Cancer Res"},{"key":"1683_CR9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1083\/jcb.200703010","volume":"177","author":"M Curto","year":"2007","unstructured":"Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI (2007) Contact-dependent inhibition of EGFR signaling by Nf2\/merlin. J Cell Biol 177:893\u2013903","journal-title":"J Cell Biol"},{"key":"1683_CR10","first-page":"1685","volume":"91","author":"M Montalembert de","year":"2006","unstructured":"de Montalembert M, Bachir D, Hulin A, Gimeno L, Mogenet A, Bresson JL, Macquin-Mavier I, Roudot-Thoraval F, Astier A, Galacteros F (2006) Pharmacokinetics of hydroxyurea 1,000\u00a0mg coated breakable tablets and 500\u00a0mg capsules in pediatric and adult patients with sickle cell disease. Haematologica 91:1685\u20131688","journal-title":"Haematologica"},{"key":"1683_CR11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cancergencyto.2008.07.006","volume":"187","author":"P Robles de","year":"2008","unstructured":"de Robles P, McIntyre J, Kalra S, Roldan G, Cairncross G, Forsyth P, Magliocco T, Hamilton M, Easaw J (2008) Methylation status of MGMT gene promoter in meningiomas. Cancer Genet Cytogenet 187:25\u201327","journal-title":"Cancer Genet Cytogenet"},{"key":"1683_CR12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ijc.1306","volume":"93","author":"M Demeule","year":"2001","unstructured":"Demeule M, Shedid D, Beaulieu E, Del Maestro RF, Moghrabi A, Ghosn PB, Moumdjian R, Berthelet F, Beliveau R (2001) Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors. Int J Cancer 93:62\u201366","journal-title":"Int J Cancer"},{"key":"1683_CR13","first-page":"1193","volume":"12","author":"AF Eichler","year":"2010","unstructured":"Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, Lynch TJ, Sequist LV (2010) EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neurooncology 12:1193\u20131199","journal-title":"Neurooncology"},{"key":"1683_CR14","first-page":"1493","volume":"23","author":"JT Fraenzer","year":"2003","unstructured":"Fraenzer JT, Pan H, Minimo L Jr, Smith GM, Knauer D, Hung G (2003) Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol 23:1493\u20131500","journal-title":"Int J Oncol"},{"key":"1683_CR15","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/0002-9149(82)90440-4","volume":"50","author":"W Frishman","year":"1982","unstructured":"Frishman W, Kirsten E, Klein M, Pine M, Johnson SM, Hillis LD, Packer M, Kates R (1982) Clinical relevance of verapamil plasma levels in stable angina pectoris. Am J Cardiol 50:1180\u20131184","journal-title":"Am J Cardiol"},{"key":"1683_CR16","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature11005","volume":"483","author":"MJ Garnett","year":"2012","unstructured":"Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR et al (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483:570\u2013575","journal-title":"Nature"},{"key":"1683_CR17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01050266","volume":"15","author":"JW Goodwin","year":"1993","unstructured":"Goodwin JW, Crowley J, Eyre HJ, Stafford B, Jaeckle KA, Townsend JJ (1993) A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol 15:75\u201377","journal-title":"J Neurooncol"},{"key":"1683_CR18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/07357900601062339","volume":"24","author":"S Grunberg","year":"2006","unstructured":"Grunberg S, Weiss M, Russell C, Spitz I, Ahmadi J, Sadun A, Sitruk-Ware R (2006) Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 24:727\u2013733","journal-title":"Cancer Invest"},{"key":"1683_CR19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11060-004-2337-3","volume":"74","author":"BM Hahn","year":"2005","unstructured":"Hahn BM, Schrell UM, Sauer R, Fahlbusch R, Ganslandt O, Grabenbauer GG (2005) Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J Neurooncol 74:157\u2013165","journal-title":"J Neurooncol"},{"key":"1683_CR20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/2050-6511-14-22","volume":"14","author":"F Kajbaf","year":"2013","unstructured":"Kajbaf F, Lalau JD (2013) The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosis. BMC Pharmacol Toxicol 14:22","journal-title":"BMC Pharmacol Toxicol"},{"key":"1683_CR21","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1038\/onc.2012.468","volume":"32","author":"N Kliese","year":"2013","unstructured":"Kliese N, Gobrecht P, Pachow D, Andrae N, Wilisch-Neumann A, Kirches E, Riek-Burchardt M, Angenstein F, Reifenberger G, Riemenschneider M, Meese E, Panayotova-Dimitrova D, Gutmann DH, Mawrin C (2013) miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene 32:4712\u20134720","journal-title":"Oncogene"},{"key":"1683_CR22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF00165657","volume":"29","author":"AP Kyritsis","year":"1996","unstructured":"Kyritsis AP (1996) Chemotherapy for meningiomas. J Neurooncol 29:269\u2013272","journal-title":"J Neurooncol"},{"key":"1683_CR23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ando.2013.02.002","volume":"74","author":"C Loubiere","year":"2013","unstructured":"Loubiere C, Dirat B, Tanti JF, Bost F (2013) New perspectives for metformin in cancer therapy. Ann Endocrinol (Paris) 74:130\u2013136","journal-title":"Ann Endocrinol (Paris)"},{"key":"1683_CR24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/B:NEON.0000021827.85754.8e","volume":"67","author":"D Loven","year":"2004","unstructured":"Loven D, Hardoff R, Sever ZB, Steinmetz AP, Gornish M, Rappaport ZH, Fenig E, Ram Z, Sulkes A (2004) Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol 67:221\u2013226","journal-title":"J Neurooncol"},{"key":"1683_CR25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1586\/era.11.175","volume":"12","author":"K Madaan","year":"2012","unstructured":"Madaan K, Kaushik D, Verma T (2012) Hydroxyurea: a key player in cancer chemotherapy. Expert Rev Anticancer Ther 12:19\u201329","journal-title":"Expert Rev Anticancer Ther"},{"key":"1683_CR26","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.3171\/FOC-07\/10\/E11","volume":"23","author":"HB Newton","year":"2007","unstructured":"Newton HB (2007) Hydroxyurea chemotherapy in the treatment of meningiomas. Neurosurg Focus 23:E11","journal-title":"Neurosurg Focus"},{"key":"1683_CR27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/02688690400012392","volume":"18","author":"H Newton","year":"2004","unstructured":"Newton H, Scott S, Volpi C (2004) Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg 18:495\u2013499","journal-title":"Br J Neurosurg"},{"key":"1683_CR28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11910-009-0034-5","volume":"9","author":"AD Norden","year":"2009","unstructured":"Norden AD, Drappatz J, Wen PY (2009a) Advances in meningioma therapy. Curr Neurol Neurosci Rep 9:231\u2013240","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1683_CR29","doi-asserted-by":"crossref","unstructured":"Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD et al (2009b) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol","DOI":"10.1007\/s11060-009-9948-7"},{"key":"1683_CR30","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/1078-0432.CCR-12-1904","volume":"19","author":"D Pachow","year":"2013","unstructured":"Pachow D, Andrae N, Kliese N, Angenstein F, Stork O, Wilisch-Neumann A, Kirches E, Mawrin C (2013) mTORC1 inhibitors suppress meningioma growth in mouse models. Clin Cancer Res 19:1180\u20131189","journal-title":"Clin Cancer Res"},{"key":"1683_CR31","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/WCO.0000000000000035","volume":"26","author":"M Preusser","year":"2013","unstructured":"Preusser M, Berghoff AS, Hottinger AF (2013) High-grade meningiomas: New avenues for drug treatment? Curr Opin Neurol 26:708\u2013715","journal-title":"Curr Opin Neurol"},{"key":"1683_CR32","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/labinvest.3700307","volume":"85","author":"S Puttmann","year":"2005","unstructured":"Puttmann S, Senner V, Braune S, Hillmann B, Exeler R, Rickert CH, Paulus W (2005) Establishment of a benign meningioma cell line by hTERT-mediated immortalization. Lab Invest 85:1163\u20131171","journal-title":"Lab Invest"},{"key":"1683_CR33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-011-0687-1","volume":"106","author":"DA Reardon","year":"2012","unstructured":"Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE 2nd, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS (2012) Phase II study of Gleevec((R)) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol 106:409\u2013415","journal-title":"J Neurooncol"},{"key":"1683_CR34","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3171\/jns.1997.86.5.0840","volume":"86","author":"UM Schrell","year":"1997","unstructured":"Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, Fahlbusch R (1997) Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 86:840\u2013844","journal-title":"J Neurosurg"},{"key":"1683_CR35","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1593\/neo.08642","volume":"10","author":"K Striedinger","year":"2008","unstructured":"Striedinger K, Vandenberg SR, Baia GS, McDermott MW, Gutmann DH, Lal A (2008) The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia 10:1204\u20131212","journal-title":"Neoplasia"},{"key":"1683_CR36","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1002\/1097-0142(19891201)64:11<2243::AID-CNCR2820641110>3.0.CO;2-S","volume":"64","author":"K Tanaka","year":"1989","unstructured":"Tanaka K, Sato C, Maeda Y, Koike M, Matsutani M, Yamada K, Miyaki M (1989) Establishment of a human malignant meningioma cell line with amplified c-myc oncogene. Cancer 64:2243\u20132249","journal-title":"Cancer"},{"key":"1683_CR37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10549-013-2511-4","volume":"139","author":"WA Teft","year":"2013","unstructured":"Teft WA, Gong IY, Dingle B, Potvin K, Younus J, Vandenberg TA, Brackstone M, Perera FE, Choi YH, Zou G, Legan RM, Tirona RG, Kim RB (2013) CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Res Treat 139:95\u2013105","journal-title":"Breast Cancer Res Treat"},{"key":"1683_CR38","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/0973-1482.95201","volume":"8","author":"Y Tsubata","year":"2012","unstructured":"Tsubata Y, Hamada A, Sutani A, Isobe T (2012) Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient. J Cancer Res Ther 8:154\u2013156","journal-title":"J Cancer Res Ther"},{"key":"1683_CR39","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1158\/1078-0432.CCR-12-0299","volume":"19","author":"A Wilisch-Neumann","year":"2013","unstructured":"Wilisch-Neumann A, Kliese N, Pachow D, Schneider T, Warnke JP, Braunsdorf WE, Bohmer FD, Hass P, Pasemann D, Helbing C, Kirches E, Mawrin C (2013) The integrin inhibitor cilengitide affects meningioma cell motility and invasion. Clin Cancer Res 19:5402\u20135412","journal-title":"Clin Cancer Res"},{"key":"1683_CR40","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.febslet.2012.03.016","volume":"586","author":"L Zhou","year":"2012","unstructured":"Zhou L, Hanemann CO (2012) Merlin, a multi-suppressor from cell membrane to the nucleus. FEBS Lett 586:1403\u20131408","journal-title":"FEBS Lett"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-014-1683-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-014-1683-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-014-1683-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T10:44:37Z","timestamp":1565433877000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-014-1683-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,11]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["1683"],"URL":"https:\/\/doi.org\/10.1007\/s00432-014-1683-6","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,11]]}}}